Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received June 29, 2015
- Accepted in final form June 16, 2016
- First Published September 2, 2016.
Article Versions
- Previous version (September 2, 2016 - 13:01).
- You are viewing the most recent version of this article.
Author Disclosures
- Douglas L. Arnold, MD,
- Elizabeth Fisher, PhD,
- Vesna V. Brinar, MD, PhD,
- Jeffrey A. Cohen, MD,
- Alasdair J. Coles, MD, PhD,
- Gavin Giovannoni, MD, PhD,
- Hans-Peter Hartung, MD, PhD,
- Eva Havrdova, MD, PhD,
- Krzysztof W. Selmaj, MD, PhD,
- Miroslav Stojanovic, MD,
- Howard L. Weiner, MD,
- Stephen L. Lake, ScD,
- David H. Margolin, MD, PhD,
- David R. Thomas, PhD,
- Michael A. Panzara, MD, MPH and
- D. Alastair S. Compston, MD, PhD
- On behalf of the CARE-MS I and CARE-MS II Investigators
- Douglas L. Arnold, MD,
Acorda Therapeutics, Biogen Idec, Genentech, Genzyme, GSK, Hoffman LaRoche, MedImmune, Mitsubishi, Novartis, Receptos, Receptos, Roche, Sanofi-Aventis
NONE
Genzyme, travel support
NONE
Method of evaluating the efficacy of drug on brain nerve cells
NONE
NONE
NONE
NONE
NONE
NONE
Biogen, Novartis
CIHR 15630 co-PI 2007 2012 CIHR 84360 co-PI 2007-2012 CIHR 84367 PI 2007-2012 CIHR 111169 coPI 2011-2014 CIHR 43871 co-PI 2010-2015
NONE
Multiple Sclerosis Society of Canada Multiple Sclerosis Research Foundation
NONE
NONE
NONE
NONE
NeuroRx Research, 2002-2013
NONE
- Elizabeth Fisher, PhD,
NONE
NONE
(1) Received travel funds and honoraria for speaking from Biogen Idec
Neurology, Editorial Board, 2012-2014
(1) patent on brain parenchymal fraction, a method of measuring brain volume
NONE
Biogen, Sr. Director, 2015-present
(1) Biogen Idec (2) Genzyme (3) Novartis
NONE
NONE
NONE
(1) Biogen Idec (2) NeuroRx/Genzyme
National Institutes of Health NINDS, P01-NS38667, PI of Project 3, 2004-2014
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Vesna V. Brinar, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jeffrey A. Cohen, MD,
Genentech 7/31/15, Consulting meeting Genzyme/Sanofi 7/22/15, Consulting meeting Merck 6/10/16, Consulting meeting Novartis 5/13/15, Steering Committee meeting Receptos 11/11/15, Steering Committee teleconference
NONE
Teva 6/12/15, Speaker, Honorarium
2015-present, Co-Editor, Multiple Sclerosis Journal - Experimental, Translational and Clinical
NONE
Cambridge University Press, JA Cohen and RA Rudick, eds, Multiple Sclerosis Therapeutics, 4th edition, 2011
NONE
NONE
NONE
NONE
NONE
Research support paid to my institution from Genzyme, Novartis, Receptos, Synthon, and Teva
Department of Defense, PR093324, PI, 2010-14 NIH, 1 RO1 NS074787, 2011-4
NONE
National MS Society, PP1752, PI, 06/2012-11/2013 Consortium of MS Centers, FWA00005367, PI, 12/2012-11/2013
NONE
NONE
NONE
NONE
NONE
NONE
- Alasdair J. Coles, MD, PhD,
(1) Multiple Sclerosis Society of GB & NI (2) International Society for Neuroimmunology
NONE
(1) Nil (2) Genzyme
NONE
(1) IL-21 as a marker of autoimmunity after alemtuzumab treatment
NONE
NONE
NONE
(1) Genzyme
NONE
NONE
NONE
2016 A randomised placebo-controlled trial of immunotherapy in patients with psychosis associated with anti-neuronal membrane antibodies (SINAPPS 2). Medical Research Council. (?2,466,231 fEC) with Co-PI: Peter Jones and Co-applicants: Belinda Lennox, Mike Zandi and James Wason.
NONE
2014 A feasibility study of immunotherapy in antibody- associated psychosis. The Stanley Medical Research Institute ($284,176) RG77862 2015 Imaging cerebral metabolism in multiple sclerosis using hyperpolarised carbon. Multiple Sclerosis Society (?39,900) as Co-PI (Ferdia Gallagher is PI) 2015 Does early treatment prevent progression? Long term follow-up of alemtuzumab patients. Multiple Sclerosis Society (?92,613) RG79876
NONE
NONE
NONE
NONE
NONE
2). Have give expert witness in the past, and possibly in the future, on patents surrounding copaxone and fingolimod as a treatment of multiple sclerosis.
I chair the MS advisory group of the Association of British Neurologists
- Gavin Giovannoni, MD, PhD,
(1)Biogen-Idec (2) Fiveprime (3) Genzyme (4) GW Pharma (5) Ironwood (6) Merck-Serono (7) Novartis (8) Roche (9) Sanofi-Aventis (10) Synthon BV (11) Teva (12) Vertex Pharmaceuticals (13) Abbvie (14) Canbex
NONE
Speaker honoraria: (1)Biogen-Idec (2) Genzyme (3) GW Pharma (4) Merck-Serono (5) Novartis (6) Roche (7) Teva
(1) Multiple Sclerosis and Related Disorders, Editor since 2011
NONE
NONE
NONE
(1)Biogen-Idec (2) Fiveprime (3) Genzyme (4) GW Pharma (5) Ironwood (6) Merck-Serono (7) Novartis (8) Roche (9) Sanofi-Aventis (10) Synthon BV (11) Teva (12) Vertex Pharmaceuticals (13) Abbvie (14) Canbex
(1) Novartis (2) Teva
NONE
NONE
Genzyme 2012-2014 Merck 2012-2014
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hans-Peter Hartung, MD, PhD,
Novartis; Merck Serono; Teva; Biogen Idec; Roche; Genzyme; BayerHealthcare; Sanofi; MedImmune; GeNeuro; Opexa; Octapharma
NONE
Speaker Honoraria from: Biogen Idec Genzyme Teva Sanofi Aventis Merck Serono Novartis Novartis Bayer Healthcare
editorial board member: annals of neurology, frontiers neurology / immunology; european journal of neurology; current opinion in neurology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eva Havrdova, MD, PhD,
1. Biogen 2. Novartis 3. Genzyme 4. Actelion 5. Celgene
NONE
1. Biogen 2. Novartis 3. Celgene 4. Genzyme 5. Actelion 6. Roche 7. Merck Serono
NONE
NONE
NONE
NONE
1. Biogen Idec 2. Novartis 3. Celgene 4. Genzyme 5. Actelion 6. Roche 7. Merck Serono
NONE
NONE
NONE
(1) Biogen, grant support for gait study (2) Merck Serono
1. European Commission Grant: ABIRISK - IMI (2012-2016), investigator 2. Czech Ministry of Education: PRVOUK-P26/LF1/4 (2013- 2016), investigator
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Krzysztof W. Selmaj, MD, PhD,
Genzyme,Biogen,Novartis,Synthon, Roche, Receptos, TEVA, Merck
NONE
Speaker for Biogen Idec, Novartis, TEVA, Bayer, Roche, Receptos, Genzyme, Travel to AAN 2016 Merck
Journal of Neuroimmunology - member of editorial board - 1994 now. Multiple Sclerosis and Demyelinating Disorders - member of editorial board sinbce 2015
NONE
NONE
NONE
1)Genzyme 2) Novartis 3) Biogen 4) Roche 5)Synthon 6)Merck Serono 7) Ono 8) Teva
1) Novartis 2) Merck-Serono 3) BiogenIdec 4) Bayer 5)Genzyme
NONE
NONE
NONE
NONE
Research grant from National Research Center (Poland)and from National Center for Research and Development (Poland)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Miroslav Stojanovic, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Howard L. Weiner, MD,
served on the advisory board for The Guthy Jackson Charitable Foundation, Teva Pharmaceutical Industries Ltd., Biogen Idec, Novartis, Sanofi-aventis
NONE
NONE
NONE
NONE
NONE
NONE
Therapix Biogen Novartis Serono Teva Sanofi
NONE
NONE
NONE
EMD Serono
NIH
NONE
National Multiple Sclerosis Society
NONE
NONE
NONE
NONE
NONE
NONE
- Stephen L. Lake, ScD,
NONE
NONE
NONE
NONE
NONE
NONE
Dr. Stephen L. Lake, as an Associate VP of Biostatistics receives personal compensation as an employee of Sanofi Genzyme (a company of Sanofi).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David H. Margolin, MD, PhD,
NONE
NONE
NONE
NONE
Treatment of Multiple Sclerosis (MS). Describes dosing regimens for alemtuzumab (Lemtrada).
NONE
Sanofi Genzyme, Senior Medical Director, 12 years (full- time)
NONE
NONE
NONE
(1) Genzyme Corp. (100%), 12 years
Sanofi Genzyme.
NONE
NONE
NONE
(1) Genzyme Corporation, a Sanofi company. (2) Contingent Value Right (GCVRZ) tied to alemtuzumab sales.
NONE
NONE
(1) Sanofi, 12 years. (2) Contingent Value Right (GCVRZ) tied to alemtuzumab sales. (Note: Author was not technically an investigator, but participated in the research as Sponsor's medical monitor.)
(1) Sanofi, 12 years. (2) Contingent Value Right (GCVRZ) tied to alemtuzumab sales.
NONE
- David R. Thomas, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Evidence Scientific Solutions, Senior Medical Writer, 3 years.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michael A. Panzara, MD, MPH and
NONE
NONE
NONE
NONE
NONE
NONE
Sanofi Genzyme, Head, MS, Neurology, and Ophthalmology Development, 6 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- D. Alastair S. Compston, MD, PhD
(1) Scientific advisory board for Genzyme (a Sanofi company)
NONE
(1) Travel paid for speaking engagements for Genzyme; honoraria paid into departmental budget and (from 2014) for personal use
NONE
IL-21 as a biomarker of autoimmunity after alemtuzumab
NONE
NONE
1) Genzyme(2) Bayer Schering
(1) Genzyme
(1) Genzyme has made gifts to the University of Cambridge
NONE
(1) Genzyme(2) Bayer Schering
Medical Research COuncil
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From NeuroRx Research (D.L.A.) and Department of Neurology and Neurosurgery (D.L.A.), Montréal Neurological Institute, McGill University, Québec, Canada; Department of Biomedical Engineering (E.F.) and Mellen Center (J.A.C.), Cleveland Clinic, OH; Zagreb Medical School and University Hospital Center (V.V.B.), Croatia; Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of Cambridge, UK; Queen Mary University of London (G.G.), Barts and the London School of Medicine, UK; Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Heinrich-Heine University, Düsseldorf, Germany; Department of Neurology (E.H.), First Medical Faculty, Charles University in Prague, Czech Republic; Department of Neurology (K.W.S.), Medical University of Łódź, Poland; Clinical Centre Kragujevac (M.S.), Clinic of Neurology, Serbia; Brigham and Women’s Hospital Center for Neurologic Diseases (H.L.W.), Boston, MA; Sanofi Genzyme (S.L.L., D.H.M., M.A.P.), Cambridge, MA; and Evidence Scientific Solutions (D.R.T.), Horsham, West Sussex, UK. Dr. Panzara is currently with Wave Life Sciences, Cambridge, MA.
- Correspondence to Dr. Arnold: douglas.arnold{at}mcgill.ca
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study
Dr. Robert Shapiro and Dr. Amynah Pradhan